Cue Biopharma, Inc. (CUE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 26, 2025, discloses significant changes in executive leadership for Cue Biopharma, Inc., a clinical-stage biopharmaceutical company. The report details the appointment of a new Chief Executive Officer (CEO) and the retirement of the incumbent CEO, effective September 29, 2025.
Key Financial Metrics and Compensation
The filing does not provide revenue, profit, cash flow, or liquidity metrics. Financial details are limited to executive compensation arrangements:
- New CEO Base Salary: Usman Azam will receive an annual base salary of $620,000.
- New CEO Bonus: Discretionary incentive bonus with a target of up to 50% of base salary.
- New CEO Equity: Granted options to purchase 1,875,000 shares (time-based) and 375,000 shares (performance-based).
- Outgoing CEO Severance: Daniel R. Passeri is entitled to a lump sum cash payment of $838,750 (representing 12 months of pre-reduction salary plus prorated bonus).
- Outgoing CEO Equity: Acceleration of time vesting by 12 months for all outstanding equity awards; granted a new option for 375,000 shares contingent on a financing milestone.
Material Changes
The primary material change is the transition of the CEO role:
- Appointment: Usman Azam appointed President, CEO, and Board member, effective September 29, 2025.
- Resignation: Daniel R. Passeri retired and resigned as CEO and Board member, effective September 29, 2025.
- Transition Role: Mr. Passeri will serve as a strategic advisor until March 30, 2026.
Outlook, Risks, and Contingencies
Management Commentary: Dr. Azam brings extensive experience from previous CEO roles at Inspirna, Empyrean Neuroscience, and Tmunity Therapeutics, as well as senior leadership at Novartis, Johnson & Johnson, and Pfizer.
Contingencies and Risks:
- Financing Milestone: Vesting of performance-based stock options for both the new CEO (375,000 shares) and the outgoing CEO's advisor role (375,000 shares) is contingent on the Company timely achieving a specified financing milestone.
- Severance Conditions: Severance payments for both executives are subject to the execution of release of claims and compliance with restrictive covenants.
- Indemnification: The Company has entered into a standard indemnification agreement with Dr. Azam, potentially exposing the Company to costs related to legal proceedings arising from his service.
Investor Verification Checklist
- Verify the specific "specified financing milestone" required to vest the performance-based stock options for both executives.
- Review the upcoming Form 10-Q for the quarter ended September 30, 2025, for the full text of the employment, separation, and advisor agreements.
- Assess the impact of the $838,750 severance payment and ongoing advisor costs on the Company's current cash runway.
- Confirm the timeline for the transition of duties between Mr. Passeri and Dr. Azam.